Abstract
Morbidity and mortality due to Rhesus antibodies in pregnant women's serum have steadily declined because of various factors which include, implementation of routine antenatal anti-D prophylaxis and development of non-invasive investigations for monitoring Rhesus affected pregnancies. Because at present this condition is so rare, any case of red-cell alloimmunization should be managed in liaison with a specialist in foetal medicine. Unlike the first immunized pregnancy, maternal antibody titres are not predictive of foetal risk in any subsequent pregnancies. Serial peak middle cerebral artery velocities using Doppler can be used in these pregnancies to detect foetal anaemia. Foetal blood type can now be determined by new techniques to detect free foetal DNA in maternal plasma. In selected cases depending on the gestational age of foetus intrauterine transfusion is necessary through ultrasound directed puncture of the umbilical cord with the direct intravascular infusion of red blood cells. Perinatal survival rates of more than 90% have been reported.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
